Syndax Operating Cash Flow Sales Ratio from 2010 to 2024

SNDX Stock  USD 16.51  0.01  0.06%   
Syndax Pharmaceuticals Operating Cash Flow Sales Ratio yearly trend continues to be fairly stable with very little volatility. Operating Cash Flow Sales Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, Syndax Pharmaceuticals Operating Cash Flow Sales Ratio regression line of annual values had significance of  0.71 and arithmetic mean of (13.28). View All Fundamentals
 
Operating Cash Flow Sales Ratio  
First Reported
2010-12-31
Previous Quarter
0.24
Current Value
0.25
Quarterly Volatility
17.20174328
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.4 K, Interest Expense of 197.6 K or Selling General Administrative of 57.1 M, as well as many indicators such as Price To Sales Ratio of 6.97, Dividend Yield of 0.0198 or PTB Ratio of 2.88. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Syndax Pharmaceuticals Correlation against competitors.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Latest Syndax Pharmaceuticals' Operating Cash Flow Sales Ratio Growth Pattern

Below is the plot of the Operating Cash Flow Sales Ratio of Syndax Pharmaceuticals over the last few years. It is Syndax Pharmaceuticals' Operating Cash Flow Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syndax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Operating Cash Flow Sales Ratio10 Years Trend
Very volatile
   Operating Cash Flow Sales Ratio   
       Timeline  

Syndax Operating Cash Flow Sales Ratio Regression Statistics

Arithmetic Mean(13.28)
Coefficient Of Variation(129.58)
Mean Deviation14.72
Median(3.87)
Standard Deviation17.20
Sample Variance295.90
Range47.2243
R-Value(0.11)
Mean Square Error315.07
R-Squared0.01
Significance0.71
Slope(0.41)
Total Sum of Squares4,143

Syndax Operating Cash Flow Sales Ratio History

2024 0.25
2023 0.24
2021 0.21
2020 -46.97
2019 -33.36
2018 -45.18
2017 -22.47

About Syndax Pharmaceuticals Financial Statements

Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' Operating Cash Flow Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cash Flow Sales Ratio 0.24  0.25 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.